Clearlake Seeks to Triple Assets at Credit Unit to $100 Billion
'In the next five-plus years, I would love to be talking about a $75 to $100 billion platform,' Clearlake co-founder and Managing Partner José E. Feliciano said in an interview. The Santa Monica, California-based firm currently manages about $30 billion in private and liquid credit investments.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Jim Cramer on Lam Research: 'Let it Come in And Then Do Some Buying'
Lam Research Corporation (NASDAQ:LRCX) is one of the stocks that Jim Cramer spoke about. When a caller asked about the company during the lightning round, Cramer replied: 'Lam Research had a great quarter. Don't believe anything else. I mean, I know the stock's rolling over because the chart's bad. I really liked it. I thought that Tim Archer did a terrific job. Let it come in and then do some buying.' Wichy/ Lam Research (NASDAQ:LRCX) provides advanced semiconductor processing equipment used in chip fabrication. The company specializes in deposition, etch, and cleaning technologies. During the July 22 episode, Cramer said, 'Don't be in a hurry' to buy the stock, as he commented: 'It would be best to accept that the food and drugs can have a couple of days in the sun, can't they? The old leaders pulled back a little, can't they? Don't be in a hurry to buy Lam Research or Applied Materials or KLA… not after we had Texas Instruments on tonight, and I wouldn't step in front of the falling knives that represent any of the meme stocks…' While we acknowledge the potential of LRCX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
13 minutes ago
- Business Wire
Codasip looks to Silicon Creations' PLL to drive RSIC-V Automotive Safety-Critical Core
ATLANTA--(BUSINESS WIRE)-- Silicon Creations, a leading provider of high-performance analog and mixed-signal intellectual property (IP) today announced that its low-area integer PLL has been successfully integrated into Codasip's latest test chip, enabling the evaluation of Codasip's L31AS dual-core lock-step CPU and crypto accelerator IP. The collaboration marks a key milestone in the deployment of robust and efficient clocking solutions for automotive-grade RISC-V systems. Designed for automotive applications, Codasip's L31AS CPU is a safety-critical, high-performance RISC-V core. To meet the stringent clocking requirements of this environment, Codasip selected Silicon Creations' low-area integer PLL for its ultra-small footprint, proven silicon track record, ease of integration, and excellent low-jitter digital clock generation. The integration delivered the precise clocking performance needed while minimizing silicon area and system complexity. 'We are thrilled to support Codasip's innovative RISC-V processor development with our area-optimized digital clocking PLL,' said Randy Caplan, co-founder of Silicon Creations. 'This partnership highlights not only the flexibility of our PLL technology but also how optimized clocking solutions can help accelerate the delivery of automotive-grade, high-performance computing platforms.' Paul Elliott, Senior Security and Safety Architect at Codasip, commented, 'The successful integration of Silicon Creations' PLL into our L31AS dual-core test chip is a significant step for Codasip. As we advance our automotive and embedded system solutions, the reliability and performance of this PLL will play a critical role in supporting our next-generation designs.' With several upcoming projects requiring precise and efficient PLL technology, Codasip's successful test chip evaluation reinforces its commitment to driving innovation in RISC-V-based technologies for the automotive and embedded markets. The collaboration with Silicon Creations demonstrates the importance of strategic IP partnerships in accelerating time-to-market while meeting stringent industry requirements. About Codasip Codasip is a leading provider of customizable processor cores and associated toolchains, specializing in RISC-V-based architectures. The company offers high-performance, energy-efficient solutions for a wide range of applications, including automotive, embedded systems, and IoT. Codasip's flexible and scalable designs meet the growing demands of the semiconductor industry with future-proof solutions. About Silicon Creations Silicon Creations provides world-class silicon intellectual property (IP) for precision and general-purpose timing PLLs, SerDes and high-speed differential I/Os. Silicon Creations' IP is in production from 3 to 180 nanometer process technologies, with 2nm GDS available for deployment. With a complete commitment to customer success, its IP has an excellent record of first silicon to mass production in customer designs. Silicon Creations, founded in 2006, is self-funded and growing. The company has development centers in Atlanta, USA, and Krakow, Poland, and worldwide sales representation. For more information, visit All reference to Silicon Creations trademarks are the property of Silicon Creations, Inc. All other trademarks mentioned herein are the property of their respective owners.
Yahoo
17 minutes ago
- Yahoo
Pfizer posts strong earnings despite Trump's new 'up to 250%' tariff threat
Pharmaceutical giant Pfizer reported better-than-expected quarterly results on Tuesday and improved its predictions for full-year profits, beating Wall Street expectations. The New York-based company reported second-quarter sales of $14.7 billion (€12.74bn) and earnings per share of $0.51 (€0.44). As of around 16.00 CEST, Pfizer shares were up over 4% at $24.58. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," chairman and CEO Albert Bourla said in a statement. "We continue to be actively engaged with policymakers as we navigate a complicated and rapidly evolving geopolitical environment while also remaining focused on advancing our business," Bourla continued. This despite several policies announced by the current US administration that could hurt drugmakers. Related Irish exports hit record high with pharmaceuticals showing major boost EU Commission loses on all counts in Pfizergate legal case In May, US President Donald Trump signed an executive order whereby pharmaceutical companies would be compelled to lower prices based on a "Most Favored Nation" policy. The price-slashing scheme seeks to ban drug companies from selling products in the US at prices above those in other developed countries. In Europe, the comparison becomes complex, as a significant portion pharmaceutical costs are covered by national healthcare or insurance systems, lowering prices for consumers. Experts warned at the time that this could slash their US revenues and affect availability. Even so, the president doubled down on his plans, sending letters last week to 17 drugmakers, calling for concrete steps to cut prices by 29 September. That includes agreeing to provide their full portfolio of existing medicines at no higher than European prices to every single Medicaid patient. On Tuesday, in an interview with CNBC, he announced that tariffs for pharmaceuticals and semiconductors would be coming in "next week". 'We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country," he told CNBC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
